（来源：荔枝新闻） 转自：荔枝新闻 今年，国家有关部门持续推进"体重管理年"行动，普及健康生活方式，"减重"成为高频健康热词。减重 说起来很简单，少吃点、多运动似乎就能瘦，但要坚持下去、维持效果不反弹，很少人能做到！ 45岁的葛先生 体重曾高达297斤 从减重来说，均衡营养最关键，根据自己的消耗量来决定自己的摄入量，而不是单纯少吃。梁辉主任 说，日常生活中也有一些减肥的小技巧。 1、一天三顿饭，顿顿不能少 现在成功减到128斤 秘诀是啥呢？ 在今天（12月27日）举行的江苏省人民医院减重患者交流会上，葛先生说，他从小就胖，工作以后压力 大，就想吃东西，吃胖了以后又焦虑，焦虑了再加倍吃，形成恶性循环。到了2017年，体重飙升到297 斤。"不能平躺着睡觉，憋得慌，每次呼吸暂停能到1分钟左右，直到自己把舌头咬痛了、流血，才能醒 过来。" 葛先生属于重度肥胖，生活方式干预已经不起作用。2017年，他接受了减重手术，一年之后，体重下降 到190斤，之后在医生指导下合理膳食、规律运动，体重持续下降到如今的128斤。"手术以后，食欲下 降，不像以前那么馋了，高油高糖食物现在是不沾的，体重没有反弹，最近还瘦了一些。"葛先生 ...

智通财经APP获悉，招商证券发布研报称，2026年医药板块在创新出海持续兑现、医疗内需分化的产业 趋势下，有望出现结构行情。创新药产业链仍是主线，除观察二代IO、减重、ADC板块的临床数据 外，尤其关注小核酸技术方向的加速发展；同时关注CXO、上游、原料药中具备景气度与业绩兑现的 公司。此外，院内外医疗需求有望温和复苏，关注医疗器械板块的业绩改善与海外放量，及服务、药 房、中药的个股机会。 招商证券主要观点如下： 药品板块：创新药是主线，BD是线索，重点关注小核酸等技术方向 创新及药品产业链 院内外医疗消费 医疗服务：2025年整体承压，观察2026年基数与DRGs政策稳定后刚需医疗的温和复苏、消费型医疗服 务与产品需求恢复与竞争格局优化，关注药企转型医美产品的机会，关注：爱尔眼科、通策医疗、固生 堂、海吉亚医疗等。中药：展望2026年企稳向上，看好中药OTC恢复和中药处方药创新转型，关注华润 三九、羚锐制药、众生药业、方盛制药、康缘药业等。血制品:供需关系短期波动、价格影响有望在基 数端逐步消化。药房：行业规范化整治加速集中度提升，持续探索新零售业态，关注业绩改善节奏：益 丰药房、大参林等。 风险提示：研发 ...

石药集团(01093)发布公告，集团开发的重组全人源抗ActRIIA/IIB单克隆抗体(JMT206)(该产品)已获美国 食品药品监督管理局(FDA)批准，可在美国开展临床试验。该产品亦已于2025年11月获得中华人民共和 国国家药品监督管理局批准在中国开展临床试验。 该产品可同时特异性结合激活素受体IIA型(ActRIIA)与IIB型(ActRIIB)，阻断激活素A(Activin A)、肌抑 素(GDF8)以及生长分化因子11(GDF11)与激活素受体II型(ActRII)的结合，从而抑制下游信号通路的激 活，减少肌肉流失，并促进骨胳肌维持与增长，以达到增肌减脂的效果。同时，该产品亦可协助GLP-1 受体激动剂实现更高质量的减重效果。本次获批的临床适应症为肥胖或超重合并至少一种体重相关合并 症人群的体重管理。 临床前研究显示，该产品表现出较高的生物利用度以及良好的有效性和安全性，具有较高的临床开发价 值。 ...

整理 | GLP1减重宝典内容团队 此前发表在《Diabetes Obesity Metabolism》杂志上的一篇研究， 揭示了替尔泊肽对减重后体脂分布模式的显著影响。 肥胖与2型糖尿病之间有密切的联系，而肥胖的人发展为2型糖尿病的可能性是其他人的10倍。先前的研究表明,不同的体脂分布模式(内 脏脂肪、皮下脂肪和肝脏脂肪)与分离的心代谢风险分布有关,可用于鉴别肥胖中临床意义上的亚表型。肥胖症患者的脂肪主要是作为内 脏而不是皮下脂肪储存,他们患心脏病和相关并发症的风险更高。 这项研究基于 SURPASS-3 MRI 亚研究，利用磁共振成像（MRI）技术，评估了替尔泊肽治疗一年后糖尿病患者的体脂分布情况，并与 性别与体质指数（BMI）相似的UK Biobank成像研究的虚拟对照组（VCGs）进行对比。 经研究发现，在替尔泊肽与德谷胰岛素治疗2型糖尿病的比较中，SURPASS-3试验的患者在治疗前后具有内脏脂肪（z-VAT）、腹部皮下 脂肪（z-aSAT）和肝脂肪（z-LF）水平的显著变化， 相较于VCG组的患者，替尔泊肽组的治疗可引起显著的内脏和肝脂肪水平下降， 但皮下脂肪略有增加。 研究结果显示: 使用替尔泊 ...

美诺华董事长兼总经理姚成志在今日举行的2025年第三季度业绩说明会上表示，公司在手订单充足，公 司在医美领域布局的JH389（主要方向是减重和控糖）项目已经于2025年Q3递交欧洲专利申请，目前欧 洲安全性试验正在顺利进行中。公司与合作方目前主要聚焦在JH389项目的生产、配方设计、科学研究 等方面，同时，该项目正在积极推动商业化落地。 ...

现在想法是保持康复训练，附带打针减重，看情况减少康复加入器械。 ...

Core Insights - The article discusses the innovative Sirona weight loss hydrogel pill, which has shown promising results in recent clinical trials for obesity management [6][8][13]. Group 1: Sirona Hydrogel Pill Overview - Sirona is a gastric-retentive, super porous, double-network polymer pill that expands rapidly in the stomach, helping to suppress appetite and reduce food intake [8]. - The unique mechanism allows Sirona to remain in the stomach for several days before being metabolized and excreted naturally [8]. Group 2: Clinical Trial Details - A pilot randomized controlled trial was conducted from February to December 2024, involving participants with a BMI between 30-40 and no type 2 diabetes [11]. - The trial included 38 participants, with 29 receiving Sirona treatment and 9 receiving a placebo, and was designed to assess feasibility, tolerability, safety, weight change, dietary intake, and metabolic/liver function indicators [14]. Group 3: Trial Results - Sirona demonstrated excellent tolerability, with 95.2% of participants completing the treatment, and no serious adverse events reported [14]. - In terms of weight loss, 25% of the Sirona group lost at least 5% of their body weight compared to 12.5% in the placebo group, with an average weight loss of 3.9% for the Sirona group versus 1.0% for the placebo group [14]. - The Sirona group also showed a significant reduction in caloric intake, averaging a decrease of 369.7 kcal compared to 93.5 kcal in the placebo group [14]. Group 4: Additional Health Benefits - Sirona also positively impacted blood sugar and liver function, with participants showing improvements in HbA1c levels and normalization of ALT levels after treatment [16].

Core Insights - Aimeike achieved a revenue of 1.865 billion yuan and a net profit of 1.093 billion yuan in the first three quarters of 2025 [1] - The company has a strong liquidity position with cash and cash equivalents of 1.18 billion yuan and trading financial assets of 1.973 billion yuan as of September 30, 2025 [1] - Aimeike's cash flow from operating activities for the first three quarters was 1.073 billion yuan, indicating robust cash generation capabilities [1] Financial Performance - Aimeike distributed cash dividends, profits, or interest payments totaling 1.513 billion yuan in the first three quarters [1] - Research and development expenses increased by 26.67% year-on-year to 237 million yuan, reflecting the company's commitment to innovation [1] - Other income reached 52.185 million yuan, and fair value changes contributed 64.307 million yuan to the financial results [2] Strategic Developments - The acquisition of a controlling stake in South Korea's REGENBiotech, Inc. resulted in a 233.54% increase in intangible assets compared to the previous year [2] - Fixed assets grew by 47.75% year-on-year, and non-current assets due within one year increased by 60.57%, primarily due to an increase in short-term financial products [2] - Aimeike's strategic initiatives include entering the hair regeneration market with the approval of Minoxidil topical solution and the registration of a new cosmetic ingredient, Glycyrrhetinic Acid A [1]

Market Overview - The market experienced a pullback last Friday, with all three major indices closing lower. The Shanghai Composite Index fell by 0.12%, the Shenzhen Component Index by 0.43%, and the ChiNext Index by 1.09% [1] - The trading volume in the Shanghai and Shenzhen markets reached 2.52 trillion yuan, an increase of 83.2 billion yuan compared to the previous trading day [1] Sector Performance - Sectors such as non-ferrous metals, storage chips, and film and television saw significant gains, while large financials, liquor, and gaming sectors faced notable declines [1] Analyst Insights Huatai Securities - Huatai Securities suggests a return to value and growth dynamics, focusing on domestic computing power chains, innovative pharmaceuticals, and robotics [2] - The firm notes that the A-share market has shown resilience after a brief profit-taking phase, with active trading and a positive medium-term outlook for the domestic economy [2] CITIC Construction Investment - CITIC Construction Investment continues to be bullish on the energy storage and lithium battery sectors, highlighting recent price adjustments in Shandong and capacity pricing in Ningxia as positive indicators for investment [3] - The firm emphasizes the importance of monitoring future demand forecasts for 2026 and ongoing policy support for the lithium battery sector [3] Kaiyuan Securities - Kaiyuan Securities indicates that the innovative pharmaceutical sector is entering a rapid growth phase, with Chinese biotech companies expected to maintain stable revenue growth and reduced net losses by mid-2025 [4] - The firm recommends focusing on seven promising innovative drug sectors over the next 6-12 months, which are poised for significant market opportunities [4]

Core Viewpoint - The article discusses a groundbreaking study published in "Nature" that reveals how weight loss can reverse cellular aging and metabolic disorders associated with obesity, highlighting the complex changes in adipose tissue post-weight loss [5][8]. Group 1: Research Findings - A study analyzed over 170,000 cells from 25 obese patients post-weight loss surgery and 24 healthy controls, revealing significant changes in adipose tissue, including an increase in immune cell infiltration, particularly macrophages, from 14% to 31% [6]. - The study found that weight loss significantly reduced the total proportion of myeloid cells in adipose tissue to 18%, and shifted macrophage phenotypes from pro-inflammatory to a milder type, indicating improved metabolic function [6][7]. - Weight loss was shown to reverse gene regulation disruptions caused by obesity, including a significant reduction in the expression of aging markers like p21, demonstrating a strong anti-aging effect [7][8]. Group 2: Implications for Metabolic Health - The research indicates that weight loss promotes overall metabolic health by inhibiting aging and related inflammation and tissue damage mechanisms [8]. - The study establishes a spatial dataset of human adipose tissue post-weight loss, providing deeper insights into the biological mechanisms behind weight reduction and its effects on metabolism [8].